Krsnaa Diagnostics (KRSNAA) Q2 2025 earnings summary

Executive summary

• Achieved strong growth in Q2 and H1 FY2025, driven by operational efficiency, increased patient footfalls, and expansion into new states and districts, with major contract wins and presence in 150+ districts across 18 states/UTs.

• Strategic investments in Apulki Healthcare for a 30-year exclusive diagnostics partnership, and partnerships with United Imaging and Medikabazaar to enhance diagnostic capabilities and expand reach.

• Focused on expanding B2B and B2C retail channels, leveraging PPP infrastructure for asset-light growth and long-term revenue visibility.

• Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024, compliant with SEBI and Indian Accounting Standards.

Financial highlights

• Q2 FY25 consolidated revenue from operations was ₹1,863.40 million, up 20% YoY; consolidated net profit was ₹195.96 million, up 87% YoY; EBITDA margin at 27%, PAT margin at 11%.

• H1 FY25 consolidated revenue was ₹3,565.72 million, up 21% YoY; net profit was ₹375.17 million, up 49% YoY.

• Standalone Q2 FY25 revenue was ₹1,787.22 million; net profit was ₹219.65 million.

• EPS for Q2 FY25: Standalone basic ₹6.80, consolidated basic ₹6.07.

• Company remains net debt-free with cash and equivalents of INR 220 crores as of September 2024.

Outlook and guidance

• Confident in achieving 25% revenue growth for FY2025, with sustainable EBITDA margins above previous guidance.

• CapEx guidance for FY2025 maintained at approximately INR 170 crores.

• Receivable days expected to normalize to around 90 by year-end, with no anticipated bad debts.

• Management expects no material impact from ongoing tax proceedings on financial position or performance as of September 30, 2024.

• Focus on tapping underpenetrated diagnostic markets via new PPP tenders and expanding retail presence.